Hamid Erfanian - 23 Nov 2022 Form 4 Insider Report for ENZO BIOCHEM INC (ENZB)

Role: Chief Executive Officer, Director
Signature: /s/ Hamid Erfanian
Issuer symbol: ENZB
Transactions as of: 23 Nov 2022
Net transactions value: +$197,000
Form type: 4
Filing time: 28 Nov 2022, 17:27:58 UTC
Previous filing: 17 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENZ	Common Stock, $0.01 Par Value	Purchase	$197,000	+100,000	+36%	$1.97	374,600	23 Nov 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENZ	Stock Option (to acquire Common Stock)	Award	$0	+300,000		$0.000000	300,000	23 Nov 2022	Common Stock	300,000	$1.97	Direct	F2
holding	ENZ	Stock Option (to acquire Common Stock)						700,000	23 Nov 2022	Common Stock	700,000	$3.39	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted Restricted Stock Units that will vest in three equal installments, beginning on November 23, 2023.
F2	The Reporting Person was granted 300,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 23, 2023.
F3	The Reporting Person was granted 700,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 8, 2022.